BioSpace News Archive

Cryoport, Inc. and the Cell and Gene Therapy Catapult (“CGT Catapult”), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.

Anika Therapeutics, Inc. announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

Emergency physicians attending the ACEP23 conference in Philadelphia this week will be the first to see the new Clarius PAL HD3, a wireless handheld whole-body ultrasound scanner combining phased and linear arrays on a single head.

Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced that it has fully enrolled patients in Cohort 1 of its Phase 1 clinical study to evaluate TGN-S11, its first drug candidate, in patients with HPV-associated cancers.

Xēnix Medical, a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nanotechnology designation of its neoWave™ line of interbody fusion implants featuring proprietary NANOACTIV™ surface technology.

Rancho BioSciences, the leading Data Science Services company based in San Diego, CA, is pleased to announce its participation in the upcoming 2023 CDISC US Interchange.

The National Institutes of Health and the National Cancer Institute recently awarded a $4 million Research Project Grant to Paula Aristizabal, MD, MAS, pediatric oncologist at Rady Children’s Hospital-San Diego and Associate Professor of Pediatrics in Pediatric Hematology/Oncology at the University of California San Diego and Moores Cancer Center to expand a pilot program aimed at improving diverse participation in pediatric cancer clinical trials.

Royal Philips, a global leader in health technology, has announced the interoperability of Philips Capsule Medical Device Information Platform with Philips Patient Information Center iX, providing hospitals with a first-of-its-kind, comprehensive patient overview.

Couragene, a genetic medicines company using novel delivery platforms, announces that its co-founders Yong-Hui Jiang and Jiangbing Zhou of Yale University, together with Elizabeth Berry-Kravis of RUSH University have been awarded a competitive UG3/UH3 grant from the NIH’s Somatic Cell Genome Editing program.

Scorpion Therapeutics, Inc. and Pierre Fabre Laboratories announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-721, Scorpion’s highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting epidermal growth factor receptor and ERBB2 Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.